Literature DB >> 16146777

Tissue transglutaminase (TG2)--a wound response enzyme.

Dilek Telci1, Martin Griffin.   

Abstract

Repair of tissue after injury depends on a series of concerted but overlapping events including, inflammation, re-epithelialization, neovascularization and synthesis and stabilization of a fibrous extracellular matrix (ECM) that is remodeled to emulate normal tissue over time. Particular members of the transglutaminase (TG) family are upregulated during wound healing and act as a novel class of wound-healing mediators during the repair process. This group of enzymes which crosslink proteins via epsilon(gamma-glutamyl) lysine bridges are involved in wound healing through their ability to stabilize proteins and also by regulating the behavior of a wide variety of cell types that are recruited to the damaged area in order to carry out tissue repair. In this article we discuss the function of the most widely expressed member of the TG family "tissue transglutaminase" (TG2) in wound repair. Using both early and recent evidence from the literature we demonstrate how the multifunctional TG2 affects the stability of the ECM, cell-ECM interactions and as a consequence cell behavior within the different phases of wound healing, and highlight how TG2 itself might be exploited for therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16146777     DOI: 10.2741/1843

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  38 in total

1.  RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signaling.

Authors:  Zhuo Wang; Russell J Collighan; Stephane R Gross; Erik H J Danen; Gertraud Orend; Dilek Telci; Martin Griffin
Journal:  J Biol Chem       Date:  2010-10-07       Impact factor: 5.157

2.  Tissue transglutaminase regulates chondrogenesis in mesenchymal stem cells on collagen type XI matrices.

Authors:  Shobana Shanmugasundaram; Sheila Logan-Mauney; Kaitlin Burgos; Maria Nurminskaya
Journal:  Amino Acids       Date:  2011-08-10       Impact factor: 3.520

3.  A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival.

Authors:  Lindsey K Boroughs; Marc A Antonyak; Richard A Cerione
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

Review 4.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

Review 5.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

6.  The transglutaminase 2 gene is aberrantly hypermethylated in glioma.

Authors:  Lisa M Dyer; Kevin P Schooler; Lingbao Ai; Corinne Klop; Jingxin Qiu; Keith D Robertson; Kevin D Brown
Journal:  J Neurooncol       Date:  2010-07-03       Impact factor: 4.130

Review 7.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

8.  Inhibition of tissue transglutaminase promotes Aβ-induced apoptosis in SH-SY5Y cells.

Authors:  Ji Zhang; Yi-Rong Ding; Rui Wang
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

9.  Prognostic role of tissue transglutaminase 2 in colon carcinoma.

Authors:  María Jesús Fernández-Aceñero; Sofía Torres; Irene Garcia-Palmero; Cristina Díaz Del Arco; J Ignacio Casal
Journal:  Virchows Arch       Date:  2016-09-13       Impact factor: 4.064

10.  Coeliac disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis.

Authors:  E Myrsky; K Kaukinen; M Syrjänen; I R Korponay-Szabó; M Mäki; K Lindfors
Journal:  Clin Exp Immunol       Date:  2008-02-14       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.